

# Martin K Church

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3180529/publications.pdf>

Version: 2024-02-01

113  
papers

7,106  
citations

57758

44  
h-index

62596

80  
g-index

117  
all docs

117  
docs citations

117  
times ranked

4884  
citing authors

#	ARTICLE	IF	CITATIONS
1	The international EAACI/GA <sup>2</sup> LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
2	A European survey of management approaches in chronic urticaria in children: EAACI pediatric urticaria taskforce. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	5
3	Total IgE as a Marker for Chronic Spontaneous Urticaria. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 206.	2.9	55
4	The Pharmacology of Antihistamines. , 2021, , .		0
5	Predictors of treatment response in chronic spontaneous urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2965-2981.	5.7	66
6	Acetylcholine-induced whealing in cholinergic urticaria – What does it tell us?. <i>Journal of Dermatological Science</i> , 2021, 103, 10-15.	1.9	2
7	Aetiopathogenesis of Urticaria. , 2021, , 9-24.		0
8	Chronic Urticaria. , 2021, , .		0
9	Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 193-214.	1.7	2
10	Bilastine: a lifetime companion for the treatment of allergies. <i>Current Medical Research and Opinion</i> , 2020, 36, 445-454.	1.9	19
11	Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 202-206.	2.4	5
12	Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 318-325.e5.	3.8	93
13	Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. <i>Nature Communications</i> , 2020, 11, 179.	12.8	32
14	The role of eosinophils in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1510-1516.	2.9	59
15	IgM and IgA in addition to IgG autoantibodies against Fc $\epsilon$ R1 $\pm$ are frequent and associated with disease markers of chronic spontaneous urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3208-3215.	5.7	50
16	Cardiac safety of second-generation H <sub>1</sub> -antihistamines when up dosed in chronic spontaneous urticaria. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1615-1623.	2.9	33
17	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1171-1172.	0.8	4
18	Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2427-2436.	5.7	136

#	ARTICLE	IF	CITATIONS
19	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1755-1761.	2.4	7
20	Skin microdialysis: methods, applications and future opportunities – an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2019, 9, 24.	3.2	26
21	On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria. <i>Theranostics</i> , 2019, 9, 829-836.	10.0	20
22	Comparison of extended intervals and dose reduction of omalizumab for asthma control. <i>Allergo Journal International</i> , 2019, 28, 1-4.	2.0	15
23	The response to treatment in chronic spontaneous urticaria depends on how it is measured. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2055-2056.e4.	3.8	9
24	H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2043-2044.	3.8	5
25	Reply to Wood et al.. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 418-419.	5.7	0
26	Untreated allergic rhinitis is a major risk factor contributing to motorcar accidents. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1395-1397.	5.7	4
27	The role and relevance of mast cells in urticaria. <i>Immunological Reviews</i> , 2018, 282, 232-247.	6.0	165
28	IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 876-882.	2.9	167
29	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e112-e113.	2.4	52
30	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1166-1167.	2.9	6
31	Red and itchy bilateral supraorbital swellings. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1503-1506.	0.8	2
32	Immunoglobulin E-Mediated Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 689.	4.8	116
33	The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. <i>Frontiers in Immunology</i> , 2018, 9, 1873.	4.8	293
34	Bilastine: a new H <sub>1</sub> -antihistamine with an optimal profile for up dosing in urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1447-1452.	2.4	16
35	Chronic Urticaria in Children. <i>JAMA Dermatology</i> , 2017, 153, 1221.	4.1	18
36	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1059-1061.e1.	2.9	167

#	ARTICLE	IF	CITATIONS
37	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1772-1781.e1.	2.9	240
38	Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1311-1320.	2.9	89
39	Atopic predisposition in cholinergic urticaria patients and its implications. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 2060-2065.	2.4	33
40	Histamine intolerance in patients with chronic spontaneous urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1774-1777.	2.4	29
41	Ethyl cellulose nanocarriers and nanocrystals differentially deliver dexamethasone into intact, tape-stripped or sodium lauryl sulfate-exposed ex vivo human skin - assessment by intradermal microdialysis and extraction from the different skin layers. <i>Journal of Controlled Release</i> , 2016, 242, 25-34.	9.9	56
42	Does Antihistamine Up-dosing Solve Chronic Spontaneous Urticaria?. <i>Current Treatment Options in Allergy</i> , 2016, 3, 416-422.	2.2	2
43	Allergy, Histamine and Antihistamines. <i>Handbook of Experimental Pharmacology</i> , 2016, 241, 321-331.	1.8	41
44	Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 454-455.	2.4	41
45	Murine and human mast cell progenitors. <i>European Journal of Pharmacology</i> , 2016, 778, 2-10.	3.5	30
46	Management and treatment of chronic urticaria (CU). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 16-32.	2.4	60
47	Galactose-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria. <i>International Archives of Allergy and Immunology</i> , 2015, 167, 250-252.	2.1	10
48	An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2043-2045.	2.4	35
49	Symptomatic dermatographism: an inadequately described disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 708-712.	2.4	48
50	Omalizumab in the treatment of aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 459-460.	3.8	33
51	H <sub>1</sub> -Antihistamines and itch in atopic dermatitis. <i>Experimental Dermatology</i> , 2015, 24, 332-333.	2.9	13
52	Wytuczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2015, 2, T1-T23.	0.0	0
53	The role of IL-33 and mast cells in allergy and inflammation. <i>Clinical and Translational Allergy</i> , 2015, 5, 33.	3.2	152
54	Omalizumab may not inhibit mast cell and basophil activation <i>in vitro</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1832-1836.	2.4	16

#	ARTICLE	IF	CITATIONS
55	The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. <i>Molecular Immunology</i> , 2015, 63, 80-85.	2.2	103
56	The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 337-342.e2.	2.9	208
57	Antihistamines. <i>Chemical Immunology and Allergy</i> , 2014, 100, 302-310.	1.7	12
58	Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria. <i>JAMA Dermatology</i> , 2014, 150, 288.	4.1	123
59	Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. <i>Journal of Dermatological Science</i> , 2014, 73, 57-62.	1.9	222
60	Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1365-1372.e6.	2.9	268
61	Nighttime sedating H <sub>1</sub> -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2014, 171, 148-154.	1.5	58
62	Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. <i>Journal of Dermatological Science</i> , 2014, 75, 88-93.	1.9	49
63	An internet survey on self-reported food allergy in Greece: clinical aspects and lack of appropriate medical consultation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 558-564.	2.4	13
64	High Molecular Weight Targets and Treatments Using Microdialysis. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 243-268.	0.6	1
65	Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update. <i>British Journal of Dermatology</i> , 2013, 168, 455-456.	1.5	29
66	Reduced skin reactivity to vasoconstrictor and vasodilator substances in atopic eczema. <i>European Journal of Dermatology</i> , 2013, 23, 812-819.	0.6	4
67	Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. <i>Current Medical Research and Opinion</i> , 2012, 28, 131-139.	1.9	35
68	Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H <sub>1</sub> -antihistamine dose escalation. <i>British Journal of Dermatology</i> , 2012, 166, 1095-1099.	1.5	53
69	Safety and efficacy of bilastine: a new H <sub>1</sub> -antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 779-793.	2.4	58
70	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study. <i>PLoS ONE</i> , 2011, 6, e23931.	2.5	47
71	Pharmacology of Antihistamines. <i>World Allergy Organization Journal</i> , 2011, 4, S22-S27.	3.5	29
72	Pharmacology of Antihistamines. <i>World Allergy Organization Journal</i> , 2011, 4, S22-S27.	3.5	38

#	ARTICLE	IF	CITATIONS
73	Chronic spontaneous urticaria in children: Itching for insight. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 1-8.	2.6	87
74	A Qualitative and Quantitative Proteomic Study of Human Microdialysate and the Cutaneous Response to Injury. <i>AAPS Journal</i> , 2011, 13, 309-317.	4.4	19
75	Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. <i>Inflammation Research</i> , 2011, 60, 1107-1112.	4.0	37
76	The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial. <i>BMC Research Notes</i> , 2011, 4, 47.	1.4	14
77	How Minimally Invasive is Microdialysis Sampling? A Cautionary Note for Cytokine Collection in Human Skin and other Clinical Studies. <i>AAPS Journal</i> , 2010, 12, 73-78.	4.4	74
78	Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. <i>British Journal of Dermatology</i> , 2010, 162, 674-676.	1.5	59
79	Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and <i>ex vivo</i> platelet aggregation in healthy males. <i>British Journal of Dermatology</i> , 2010, 163, 1330-1332.	1.5	39
80	The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 676-682.	2.9	278
81	What Can Microdialysis Tell Us About the Temporal and Spatial Generation of Cytokines in Allergen-Induced Responses in Human Skin <i>In Vivo</i> ?. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2799-2806.	0.7	44
82	Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. <i>Brain</i> , 2004, 127, 315-320.	7.6	157
83	Human ocular mast cells. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002, 2, 419-422.	2.3	36
84	A microdialysis method for the recovery of IL-1 $\beta$ , IL-6 and nerve growth factor from human brain <i>in vivo</i> . <i>Journal of Neuroscience Methods</i> , 2002, 119, 45-50.	2.5	110
85	Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 449-454.	2.9	38
86	Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2001, 132, 286-292.	5.4	22
87	Nedocromil sodium inhibits histamine-induced itch and flare in human skin. <i>British Journal of Pharmacology</i> , 2001, 132, 613-616.	5.4	16
88	Tear and conjunctival changes during the allergen-induced early- and late-phase responses. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 948-954.	2.9	125
89	Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 607-611.	5.7	22
90	Human lung mast cells are enriched in the capacity to produce granulocyte-macrophage colony-stimulating factor in response to IgE-dependent stimulation. <i>European Journal of Immunology</i> , 1998, 28, 708-715.	2.9	35

#	ARTICLE	IF	CITATIONS
91	Human mast cells express stem cell factor. , 1998, 186, 59-66.		104
92	Studies into the Mechanisms of Dermal Inflammation Using Cutaneous Microdialysis. International Archives of Allergy and Immunology, 1997, 113, 131-133.	2.1	14
93	Release of Mast-Cell-derived Mediators after Endobronchial Adenosine Challenge in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 624-629.	5.6	153
94	The Role of the Mast Cell in Acute and Chronic Allergic Inflammation. Annals of the New York Academy of Sciences, 1994, 725, 13-21.	3.8	15
95	Differences in the distribution and characteristics of tachykinin NK <sub>1</sub> binding sites between human and guinea pig lung. British Journal of Pharmacology, 1994, 113, 1407-1415.	5.4	16
96	Modulation of the chemotactic responsiveness of guinea pig neutrophils to hRL-8 and fMLP. Journal of Leukocyte Biology, 1994, 56, 776-783.	3.3	14
97	A comparison of the effects of polyarginine and stimulated eosinophils on the responsiveness of the bovine isovolumic bronchial segment preparation. British Journal of Pharmacology, 1993, 109, 553-561.	5.4	8
98	Density Profile of Bronchoalveolar Lavage Eosinophils in the Guinea Pig Model of Allergen-induced Late-phase Allergic Responses. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 340-348.	2.9	12
99	Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. Journal of Pathology, 1990, 162, 119-126.	4.5	164
100	Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action.. British Journal of Clinical Pharmacology, 1990, 30, 89S-98S.	2.4	23
101	Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. British Journal of Pharmacology, 1989, 97, 898-904.	5.4	152
102	Human mast cell tryptase: a biochemical marker for mast cell degranulation. Biochemical Society Transactions, 1989, 17, 728-729.	3.4	8
103	The contribution of mast cell mediators to acute allergic reactions in human skin and airways. Allergy: European Journal of Allergy and Clinical Immunology, 1988, 43, 22-31.	5.7	17
104	Inhibition by nedocromil sodium of early and late phase bronchoconstriction and airway cellular infiltration provoked by ovalbumin inhalation in conscious sensitized guinea-pigs. British Journal of Pharmacology, 1988, 94, 6-8.	5.4	41
105	Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. British Journal of Pharmacology, 1988, 95, 121-130.	5.4	193
106	Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. British Journal of Pharmacology, 1987, 90, 421-429.	5.4	236
107	Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells. British Journal of Pharmacology, 1986, 87, 233-242.	5.4	51
108	The effect of an anti-allergic, nasal decongestant combination (Dimotapp™) and sodium cromoglycate nose drops on the histamine content of adenoids, middle ear fluid and nasopharyngeal secretions of children with secretory otitis media. Current Medical Research and Opinion, 1983, 8, 392-394.	1.9	8

#	ARTICLE	IF	CITATIONS
109	The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. <i>British Journal of Pharmacology</i> , 1983, 78, 671-679.	5.4	79
110	Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A <sub>2</sub> receptor mediated mechanism. <i>British Journal of Pharmacology</i> , 1983, 80, 719-726.	5.4	98
111	Anaphylactic Release of Prostaglandins from Dispersed Human Lung Cells. <i>Clinical Science</i> , 1983, 64, 40P-40P.	4.3	6
112	INHIBITION OF HISTAMINE RELEASE FROM HUMAN LUNG <i>in vitro</i> BY ANTIHISTAMINES AND RELATED DRUGS. <i>British Journal of Pharmacology</i> , 1980, 69, 663-667.	5.4	102
113	THE ACTIVITY OF SODIUM CROMOGLYCATE ANALOGUES IN HUMAN LUNG <i>in vitro</i> : A COMPARISON WITH RAT PASSIVE CUTANEOUS ANAPHYLAXIS AND CLINICAL EFFICACY. <i>British Journal of Pharmacology</i> , 1980, 70, 307-311.	5.4	32